Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

1,300

Participants

Timeline

Start Date

October 31, 2024

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2027

Conditions
Heart Failure
Interventions
DRUG

Βeta-Blockers discontinued (with tapering)

"The experimental group will undergo discontinuation of their beta-blockers treatment during the study period.~The tapering of beta-blocker will start on the day after randomisation and is based on a reduction by half-dose every 48 hours (1/2 maximally recommended dose for 48 hours, then ¼ maximally recommended dose for 48 hours) until reaching the minimal recommended dosage (1/8 maximally recommended dose) for 48 hours before complete interruption of treatment. Consequently, the tapering will not be needed in patients already receiving the minimal recommended dosage (i.e., 1/8 dose) at inclusion, and these patients will be instructed to stop taking beta-blockers the day after randomisation."

Trial Locations (1)

75015

Hôpital Européen Georges Pompidou, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT06518694 - Beta-blOckers discoNtinuation in Patients Presenting Heart FaIlure With REcovered Left Ventricular Ejection Fraction | Biotech Hunter | Biotech Hunter